Dynavax Technologies Corporations (NAS: DVAX), a commercial stage biopharmaceutical company focused on developing and commercializing novel vaccines, has appointed Elaine Sun to its Board of Directors.
Elaine brings over two decades of experience in investment banking and the life sciences. She has led and played key roles in multiple mergers, acquisitions and financings, valued in excess of $50 billion. Prior to her most recent role of Chief Financial Officer at Halozyme, Elaine served as Chief Financial and Chief Strategy Officer at SutroVax, a private biopharmaceutical developing vaccines to prevent serious infectious disease. Before moving to industry, Elaine spent two years as Managing Director and Head of West Coast Healthcare for Evercore Partners and over a decade as a Managing Director at Merrill Lynch.
Elaine received her B.A. from Wellesley College and her M.B.A. from Harvard Business School.
